Immunotherapy-boosted chemo shows striking early results against high-risk nasopharyngeal cancer
A prospective phase II pilot study from non-endemic Sichuan reports 95.2 percent response rates and 80 percent event-free survival at ...
A prospective phase II pilot study from non-endemic Sichuan reports 95.2 percent response rates and 80 percent event-free survival at ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine